Deep dives into the breakthroughs that are revolutionizing health care

STAT Reports give you the information you need to stay abreast of the fast-changing world of biotech, pharma, and health science, with original reporting by our expert staff on the companies, technologies, and personalities to watch. 

Decoding Medicare: 10 key decisions and how they're made

Will Medicare pay? The answer to that question often means success or failure for novel drugs and devices, influences the choices made by private insurance plans, and affects the adoption of emerging technologies like gene and cell therapies and artificial intelligence.

But Medicare’s decisions about coverage usually come wrapped in all-but-impenetrable directives and policy statements, accompanied by a slew of acronyms. Learn more about this report.

Clinical trial delays: what they mean and why you should care

When it comes to clinical trials, time is money. And a delay in a trial can mean a drop in a drug’s net value, lost ground to competitors, or an increased risk of failure — or it can signal more bad news to come.

But not all trial delays are red flags. How often is a pushed-back timeline a bad omen? How often is it a minor inconvenience? And how can you predict the difference? It’s not as easy as it sounds: It can be hard to get full information about trial delays, and details are often even sparser if the sponsor is a large pharma company or a private biotech. Learn more about this report.

Treating Depression: A new era of promising drugs

A new generation of drugs for depression is stirring excitement and transforming the way scientists and clinicians diagnose, treat, and think about the illness. In a field that for decades has seen little significant innovation, these novel drugs — more than 60 are in the pipeline — raise the prospect of pharmaceutical treatments that are more precise, more individualized and more effective than any of their predecessors. And companies are racing to develop compounds that can dominate the market, as Prozac and Zoloft did in the 1990s. Learn more about this report

Targeting cancer: the new frontier of immunotherapy and precision oncology

New technologies for fighting cancer are extending some patients’ lives and hold the vast potential to do the same for many others — in some cases offering cures for diseases that were once considered a death sentence. Immunotherapies rely on biological targets that scientists can use to turn the immune system into a weapon that kills cancer cells or disables the malignant cells’ defenses. This report is an authoritative guide to these game-changing treatments, informed by STAT’s original reporting and expert analysis. Learn more about this report.

The future of messenger RNA: Covid vaccines were just the beginning

Messenger RNA, the same genetic material that pharmaceutical companies quickly harnessed to develop game-changing Covid-19 vaccines, is opening up a world of possibilities, and arming doctors with new tools to prevent or combat disease: vaccinations to treat cancer, drugs that turn cells into factories for missing or faulty proteins, treatments that send tiny gene editors into the body to correct mistakes in DNA. Learn more about this report.

Health care’s big bet on blockchain

It’s not just Bitcoin. In the fiercely competitive world of health care, blockchain technology is quickly becoming the next frontier, offering hospitals, insurance companies, health tech startups and others in the industry the potential to, among other things, increase the protection of patient data, cut costs and create a stronger bulwark against fraud. Think of this report as your guide to health care’s big blockchain bet. Learn more about this report.

2022 Update: Ranking biotech's top venture capital firms

Which venture capital firms get the best returns? Our latest STAT Report is an update of our most popular report to date, this time with 2021 data. In it, STAT’s Kate Sheridan provides a definitively ranked list of more than a dozen of the biggest names in biotech investment, including Third Rock Ventures, OrbiMed, ARCH Venture Partners, and Flagship Pioneering. Learn more about this report.

The race for longevity: How scientists — and industry — are seeking to extend healthy lives

In the early 1990s, biologist Cynthia Kenyon discovered that an alteration to a single gene of a tiny, transparent worm could double the creature’s lifespan. The discovery spawned the field of longevity research, sending scientists chasing after the biochemical secrets that long-lived species like bowhead whales and naked mole rats carry coiled within their cells. This report first examines the science behind this nascent industry, exploring what we know about the biology of aging and the various types of interventions scientists are studying to help slow or even reverse its corrosive effects. Then, we present the leading companies in the space right now and the status of their drug development efforts. We’ll look too, at the vast array of age-related conditions that these companies are hoping to treat at their root cause. Lastly, this report considers the need for such developments. Learn more about this report.

The need for speed and safety: A primer on the FDA's drug approval pathways

The Food and Drug Administration’s traditional approval process involves a series of rigorous clinical trials that can take as long as a decade to set up, oversee, and evaluate. The agency has become more flexible with this standard, especially in cases where medicines may help people facing fatal or debilitating diseases. Now, however, some of the ways the FDA speeds up the drug approval process are coming under increasing scrutiny. Our latest report unpacks the differences between the different ways the FDA approves drugs, like accelerated approvals, fast-track designations, and emergency use authorizations  — and how those pathways could change in the future. Learn more about this report.

Continuous glucose monitoring: how it's advancing diabetes care

Gone are the days where a type 1 diabetes diagnosis meant a lifetime of finger pricking and injections. Today, almost half of the 4 million Americans living with type 1 diabetes use devices called continuous glucose monitors, or CGMs, to monitor their glucose and regulate their insulin levels in real-time. As the market for CGMs grows — to $5 billion in 2021, by some estimates — so too does the optimism that they will also be able to help manage the flood of unmanaged type 2 diabetes. In our latest report, written by STAT’s Katie Palmer, we’ve gathered our best intelligence on the burgeoning industry of CGM, and where it’s likely to head next. Learn more about this report.

The ‘shroom boom’: The meteoric rise of the psychedelic medicine industry

It may come as a shock, but the world of psychedelic drugs has gone legit. With long-stigmatized drugs like Eskatamine, MDMA and psilocybin advancing rapidly through clinical trials for treatments of a range of mental health conditions, entrepreneurs and investors alike are flooding the market. Our latest report, written by STAT’s Olivia Goldhill, explores the opportunities for growth in this nascent industry — and the regulations and patenting barriers that could stymie profit. Learn more about this report.

2021 Update: Ranking biotech's top venture capital firms

Which venture capital firms get the best returns? Our latest STAT Report is an update of our most popular report to date, this time with 2020 data. In it, STAT’s Kate Sheridan answers provides a definitively ranked list of more than a dozen of the biggest names in biotech investment: including Third Rock Ventures, OrbiMed, ARCH Venture Partners, and even Flagship Pioneering. Learn more about this report.

The revitalization of the antibiotic drug pipeline

As the world stares down the developing threat of antibiotic-resistant superbugs, the antibiotic pipeline — and the critical gap in the research and development of novel drugs — is garnering renewed attention. Our latest STAT Report, written by STAT pharmaceutical powerhouse Ed Silverman, explores the factors that have led to the rise of antimicrobial resistance in recent years. It also considers the social, political and economic factors that have led small biotechs and behemoth drug makers alike to shorten their antibiotic pipelines, and the solutions for addressing that. Learn more about this report.

Good bacteria: The microbiome, its vast therapeutic potential, and the challenges ahead

In the late 1950s a radical idea was born: What if a patients’ gastrointestinal inflammation could be cured by implanting a healthier gut? The result, now known as a fecal microbiota transplant, is the foundation, 60 years later, of the microbiome industry. This report examines the science behind this nascent industry, fleshing out what we know about the ecology of the human microbiome and the various interventions scientists are studying to help keep or make it healthy. It also looks at the vast array of conditions that microbiome companies are hoping to treat, and the challenges that these biotechs face in research, manufacturing, regulation and ultimately bringing these treatments to the clinic. Learn more about this report.

Understanding synthetic biology, featuring 10 companies to watch

Synthetic biology is not a new field. But it’s moving at warp speed thanks to advances in machine learning, artificial intelligence, and automation. Investment in companies working in this field are rapidly expanding, with the industry receiving $7.8 billion in private and public financing in 2020 — nearly 2 1/2 times the amount poured into the industry in 2019. This report will help you develop a deeper understanding of synthetic biology and key players. In addition to explaining the tools at the heart of synthetic biology, the report offers a closer look at 10 companies taking the field by storm, including, Synlogic, Twist Biosciences, eGenesis, and Strateos. Learn more about this report.

Nanotechnology in Medicine

If you’ll pardon the pun, nanotechnology is big. The science of manipulating molecules and materials under 100 nanometers in size is spurring advances in drug development, diagnosis, and treatment. In our latest STAT Report, we look at the different kinds of nanomaterials being developed for medical applications, how they work, and the treatments in which they are being used. We also examine the key companies involved in bringing nano-products to market; the challenges they’re facing in demonstrating safety and efficacy; and the ways they’re trying to overcome them. Learn more about this report.

The Emerging Role of Remote Patient Monitoring

As health care grows increasingly virtual, a shift accelerated by the Covid-19 pandemic, tech giants and startups alike are racing to stake out their territory, rapidly developing tools that can monitor health — or even diagnose disease — from a distance. But regulators are struggling to keep pace with technological advances, and remote patient monitoring still faces significant obstacles to reach its market potential. This STAT Report explores the hope and the hype of this emerging industry, and examines the leaders of some of the sector’s most promising and prominent companies. Learn more about this report.

2020 Edition: Ranking biotech's top venture capital firms

Which venture capital firms get the best returns? In this 50-page STAT Report, Kate Sheridan answers just this with a definitively ranked list of more than a dozen of the biggest names in biotech investment: including Third Rock Ventures, OrbiMed, ARCH Venture Partners, and even Flagship Pioneering. Learn more about this report.

STAT’s guide to interpreting clinical trial results

Interpreting clinical trial results is not for the faint of heart. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading scientific results — and you can learn it. In this report, STAT’s Sharon Begley and Adam Feuerstein provide basic tools to help you read clinical trial results with an appropriately skeptical (or at least critical) eye. They also examine specific examples of spin, noting the sections of papers reporting the results of clinical trials where they appear — and why that matters. Learn more about this report.

The 20 Executives — and Companies — to Know in Chinese Biotech

In China, biotechnology long lagged behind the industry in the West. Now, thanks to billions of dollars in state and private investment — and dramatic regulatory changes — what took a half century of iteration in the U.S. has happened over the course of about 20 years in China. In this STAT Report, we feature the 20 most important executives leading this revolution. Learn more about this report.

Gene therapies were once dismissed as too dangerous to introduce to the treatment landscape. But today they are making a comeback with hundreds of products in the pipeline and under trial. In this STAT Report, we dive into the science, and business, of viral vector technologies. We spoke with executives from 18 companies to identify the pipeline of therapies that are nearing the clinic, the engineering and production challenges that may stifle progress, and how key players are looking to overcome those challenges. Our aim: to make the problems, stakes, and possibilities clear to everyone — whether you’re an executive, investor, or policymaker actively working in the space, or patients and families interested in learning more. Learn more about this report.

Biosimilars — nearly identical versions of biologic drugs — have been heralded as a salve for the skyrocketing costs of prescription medications used to treat a wide variety of diseases. But so far they have been a disappointment. In this STAT Report, we dive into the regulations and manufacturing limitations that have acted as barriers to entry, as well as the companies that have managed to succeed in the space. Learn more about this report.

This 140-page report profiles over 50 venture capital firms that invest in biotechnology — from firms that specialize in biotech (or in health care in general), to generalists who are pumping money into the broader technology sector, with biotech as part of the mix. This is an ideal report for startups looking to raise venture capital, and to navigate the field of opportunity from coast to coast. Learn more about this report.

Stay in the loop

To get alerts when new reports are released, sign up today.